Volume 152, Issue 4, Pages 787-798.e2 (March 2017) No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease  Joseph A. Murray, Ciarán P. Kelly, Peter H.R. Green, Annette Marcantonio, Tsung-Teh Wu, Markku Mäki, Daniel C. Adelman S. Ansari, K. Ayub, A. Basile, C. Behrend, P. Bercik, B. Bressler, V. Byrnes, V.S. Chandan, V. Cheekati, B. Chipps, A. Coates, A. Collatrella, J. Condemi, C. Corder, J. Corren, C. Curtis, M. DeMeo, T. Desta, C. Devereaux, A. DiMarino, M. DuPree, C. Ennis, R. Fedorak, R. Fogel, S. Freeman, B. Freilich, K. Friedenberg, D. Geenen, K. Gill, A. Goldsobel, J. Goldstein, M. Goldstein, G. Gordon, R. Hardi, L. Harris, R. Holmes, K. Jagarlamundi, G. James, M. Kaplan, J. Kirstein, A. Knoll, R. Kotfila, R. Krause, A. Kravitz, M. Kreines, M.L. Lähdeaho, M. Lamet, K. Laskin, B. Lebwohl, D. Leffler, S. Lewis, S. Liakos, K. Lundin, K. Marks, K. Merkes, S. Minton, S. Moussa, V. Narayen, V. Nehra, E. Newton, A. Nyberg, J. Oosthuizen, T. Otrok, D. Patel, C. Pepin, R. Phillips, G. Pyle, M. Reichelderfer, B. Reid, T. Ritter, S. Saini, D. Sanders, M. Schulman, C. Semrad, S. Shah, D. Stockwell, C. Strout, D. Suez, H. Tatum, M.S. Torbenson, M. Turner, P. Varunok, M. Vazquez-Roque, A. Vento, T. Welton, R. Wohlman, M. Wood, S. Woods, K. Yousef Joseph A. Murray, Ciarán P. Kelly, Peter H.R. Green, Annette Marcantonio, Tsung-Teh Wu, Markku Mäki, Daniel C. Adelman S. Ansari, K. Ayub, A. Basile, C. Behrend, P. Bercik, B. Bressler, V. Byrnes, V.S. Chandan, V. Cheekati, B. Chipps, A. Coates, A. Collatrella, J. Condemi, C. Corder, J. Corren, C. Curtis, M. DeMeo, T. Desta, C. Devereaux, A. DiMarino, M. DuPree, C. Ennis, R. Fedorak, R. Fogel, S. Freeman, B. Freilich, K. Friedenberg, D. Geenen, K. Gill, A. Goldsobel, J. Goldstein, M. Goldstein, G. Gordon, R. Hardi, L. Harris, R. Holmes, K. Jagarlamundi, G. James, M. Kaplan, J. Kirstein, A. Knoll, R. Kotfila, R. Krause, A. Kravitz, M. Kreines, M.L. Lähdeaho, M. Lamet, K. Laskin, B. Lebwohl, D. Leffler, S. Lewis, S. Liakos, K. Lundin, K. Marks, K. Merkes, S. Minton, S. Moussa, V. Narayen, V. Nehra, E. Newton, A. Nyberg, J. Oosthuizen, T. Otrok, D. Patel, C. Pepin, R. Phillips, G. Pyle, M. Reichelderfer, B. Reid, T. Ritter, S. Saini, D. Sanders, M. Schulman, C. Semrad, S. Shah, D. Stockwell, C. Strout, D. Suez, H. Tatum, M.S. Torbenson, M. Turner, P. Varunok, M. Vazquez-Roque, A. Vento, T. Welton, R. Wohlman, M. Wood, S. Woods, K. Yousef  Gastroenterology  Volume 152, Issue 4, Pages 787-798.e2 (March 2017) DOI: 10.1053/j.gastro.2016.11.004 Copyright © 2017 AGA Institute Terms and Conditions

Figure 1 The study design consisted of an initial 4-week screening period. Once patients were recruited, there was an approximate 5-week period during which patients were not administered any medication, but recorded their symptoms. Patients whose symptoms reached the predetermined threshold then underwent endoscopy. Patients who met the threshold of a Vh:Cd ratio of 2 or less then were randomized into the active 12-week study. This was followed by a 4-week placebo run-out period. The first approximately 120 patients were recruited to have a 12-week extension so their participation in active treatment was 24 weeks. EGD, esophagogastroduodenoscopy. Gastroenterology 2017 152, 787-798.e2DOI: (10.1053/j.gastro.2016.11.004) Copyright © 2017 AGA Institute Terms and Conditions

Supplementary Figure 1 Flow diagram for the CeliAction Study. Gastroenterology 2017 152, 787-798.e2DOI: (10.1053/j.gastro.2016.11.004) Copyright © 2017 AGA Institute Terms and Conditions